Evidence map›Paper›PMID 37923782›Full record

ArticleScientific reports2023

Expression of G protein-coupled receptor GPR19 in normal and neoplastic human tissues.

Lorena Gerlach, Anna-Sophia Liselott Beyer, Daniel Kaemmerer, Jörg Sänger, Katja Evert, Stefan Schulz, Amelie Lupp

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Histopathology of C Cells and Medullary Thyroid Carcinoma.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lorena Gerlach *Institute of Pharmacology and Toxicology, Jena University Hospital, Jena, Germany.
Anna-Sophia Liselott Beyer *Institute of Pharmacology and Toxicology, Jena University Hospital, Jena, Germany.
Daniel KaemmererDepartment of General and Visceral Surgery, Zentralklinik Bad Berka, Bad Berka, Germany.
Jörg SängerLaboratory of Pathology and Cytology Bad Berka, Bad Berka, Germany.
Katja EvertDepartment of Pathology, University of Regensburg, Regensburg, Germany.
Stefan SchulzInstitute of Pharmacology and Toxicology, Jena University Hospital, Jena, Germany.
Amelie LuppInstitute of Pharmacology and Toxicology, Jena University Hospital, Jena, Germany. Amelie.Lupp@med.uni-jena.de.
Jena University Hospital · DEZentralklinik Bad Berka · DEUniversity of Regensburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Little is known about the expression of the orphan G protein-coupled receptor GPR19 at the protein level. Therefore, we developed a rabbit antibody, targeting human GPR19. After verification of the antibody specificity using GPR19-expressing cell lines and a GPR19-specific siRNA, the antibody was used for immunohistochemical staining of a variety of formalin-fixed, paraffin-embedded normal and neoplastic human tissue samples. In normal tissues, GPR19 expression was detected in a distinct cell population within the cortex, in single cells of the pancreatic islets, in intestinal ganglia, gastric chief cells, and in endocrine cells of the bronchial tract, the gastrointestinal tract, and the prostate. Among the 30 different tumour entities investigated, strong GPR19 expression was found in adenocarcinomas, typical and atypical carcinoids of the lung, and small cell lung cancer. To a lesser extent, the receptor was also present in large cell neuroendocrine carcinomas of the lung, medullary thyroid carcinomas, parathyroid adenomas, pheochromocytomas, and a subpopulation of pancreatic neuroendocrine neoplasms. In lung tumours, a negative correlation with the expression of the proliferation marker Ki-67 and a positive interrelationship with patient survival was observed. Overall, our results indicate that in adenocarcinomas and neuroendocrine tumours of the lung GPR19 may serve as a suitable diagnostic or therapeutic target.

Indexed as

AdenocarcinomaAdrenal Gland NeoplasmsCarcinoma, NeuroendocrineLung NeoplasmsNeuroendocrine TumorsAnimalsHumansMaleNerve Tissue ProteinsRabbitsReceptors, G-Protein-CoupledReceptors, NeurotransmitterGPR19 protein, humanNerve Tissue ProteinsReceptors, G-Protein-CoupledReceptors, Neurotransmitter

Identifiers

PMID37923782
PMCPMC10624815
OpenAlexW4388292478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.